Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors

BACKGROUND: Ovarian cancer is the most fatal gynecologic malignancy in the United States. While chemotherapy is effective in the vast majority of ovarian cancer patients, recurrence and resistance to standard systemic therapy is nearly inevitable. We discovered that activation of the non-receptor ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Crean-Tate, Katie K., Braley, Chad, Dey, Goutam, Esakov, Emily, Saygin, Caner, Trestan, Alexandria, Silver, Daniel J., Turaga, Soumya M., Connor, Elizabeth V., DeBernardo, Robert, Michener, Chad M., Rose, Peter G., Lathia, Justin, Reizes, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063392/
https://www.ncbi.nlm.nih.gov/pubmed/33888137
http://dx.doi.org/10.1186/s13048-021-00797-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063392/
https://www.ncbi.nlm.nih.gov/pubmed/33888137
http://dx.doi.org/10.1186/s13048-021-00797-x

Ejemplares similares